FI973118A0 - Lymfotoxin-alfa/beta-komplex och antilymfotoxin-beta-reseptorantikroppar som antitumörmedel - Google Patents

Lymfotoxin-alfa/beta-komplex och antilymfotoxin-beta-reseptorantikroppar som antitumörmedel

Info

Publication number
FI973118A0
FI973118A0 FI973118A FI973118A FI973118A0 FI 973118 A0 FI973118 A0 FI 973118A0 FI 973118 A FI973118 A FI 973118A FI 973118 A FI973118 A FI 973118A FI 973118 A0 FI973118 A0 FI 973118A0
Authority
FI
Finland
Prior art keywords
beta
activating agent
lhc
carrier
lymphotoxin
Prior art date
Application number
FI973118A
Other languages
English (en)
Finnish (fi)
Other versions
FI973118A (sv
FI119359B (sv
Inventor
Jeffrey L Browning
Werner Meier
Christopher D Benjamin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of FI973118A0 publication Critical patent/FI973118A0/sv
Publication of FI973118A publication Critical patent/FI973118A/sv
Application granted granted Critical
Publication of FI119359B publication Critical patent/FI119359B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI973118A 1995-01-26 1997-07-25 Lymfotoxin-alfa/beta-komplex och antilymfotoxin-beta-reseptorantikroppar som antitumörmedel FI119359B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
US37896895 1995-01-26
US9601386 1996-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (3)

Publication Number Publication Date
FI973118A0 true FI973118A0 (sv) 1997-07-25
FI973118A FI973118A (sv) 1997-09-25
FI119359B FI119359B (sv) 2008-10-31

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973118A FI119359B (sv) 1995-01-26 1997-07-25 Lymfotoxin-alfa/beta-komplex och antilymfotoxin-beta-reseptorantikroppar som antitumörmedel

Country Status (25)

Country Link
EP (2) EP0809510B1 (sv)
JP (2) JPH10513161A (sv)
KR (2) KR100475492B1 (sv)
CN (3) CN1589902A (sv)
AT (1) ATE268604T1 (sv)
AU (1) AU725351B2 (sv)
BG (1) BG62599B1 (sv)
BR (1) BR9606808A (sv)
CA (1) CA2211443A1 (sv)
CZ (1) CZ298711B6 (sv)
DE (1) DE69632681T2 (sv)
DK (1) DK0809510T3 (sv)
EA (1) EA000096B1 (sv)
EE (1) EE04453B1 (sv)
ES (1) ES2220972T3 (sv)
FI (1) FI119359B (sv)
HK (1) HK1006356A1 (sv)
HU (1) HUP9801746A3 (sv)
NO (1) NO322744B1 (sv)
NZ (1) NZ303405A (sv)
PL (1) PL185364B1 (sv)
PT (1) PT809510E (sv)
RO (1) RO118634B1 (sv)
SK (1) SK286497B6 (sv)
WO (1) WO1996022788A1 (sv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
PT1119370E (pt) 1998-10-09 2006-09-29 Univ Emory Inversao do estado de choque sistemico e de dificuldade respiratoria originado por inducao viral por meio do bloqueio da via da linfotoxina beta
JP2004532608A (ja) * 2000-10-13 2004-10-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ヒト化抗ＬＴ−β−Ｒ抗体
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
AU2003299984A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
AU2003303339A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
WO2008042436A2 (en) 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
US8067375B2 (en) 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2737379A1 (en) * 2008-09-30 2010-04-08 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
AU2012348017A1 (en) * 2011-12-05 2014-07-03 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
EP3247728B1 (en) 2015-01-20 2020-04-15 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
ES2157889T3 (es) * 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
DE69334224D1 (de) * 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon

Also Published As

Publication number Publication date
EP0809510B1 (en) 2004-06-09
BR9606808A (pt) 1997-12-30
DK0809510T3 (da) 2004-10-04
CN1589902A (zh) 2005-03-09
CZ298711B6 (cs) 2008-01-02
DE69632681T2 (de) 2005-06-09
EP0809510A1 (en) 1997-12-03
HUP9801746A2 (hu) 1998-11-30
ATE268604T1 (de) 2004-06-15
CA2211443A1 (en) 1996-08-01
BG101855A (en) 1998-04-30
CN1146442C (zh) 2004-04-21
SK286497B6 (sk) 2008-11-06
EE04453B1 (et) 2005-04-15
NO973385D0 (no) 1997-07-22
SK98697A3 (en) 2000-02-14
CZ236197A3 (cs) 1998-02-18
FI973118A (sv) 1997-09-25
ES2220972T3 (es) 2004-12-16
EP1407781A1 (en) 2004-04-14
BG62599B1 (bg) 2000-03-31
NO322744B1 (no) 2006-12-04
JP2007169296A (ja) 2007-07-05
KR100475492B1 (ko) 2005-03-14
AU725351B2 (en) 2000-10-12
CN1900116A (zh) 2007-01-24
DE69632681D1 (de) 2004-07-15
MX9705629A (es) 1997-10-31
CN1177302A (zh) 1998-03-25
JPH10513161A (ja) 1998-12-15
AU4970496A (en) 1996-08-14
EA199700144A1 (ru) 1997-12-30
WO1996022788A1 (en) 1996-08-01
KR19980701816A (ko) 1998-06-25
FI119359B (sv) 2008-10-31
NO973385L (no) 1997-09-25
EA000096B1 (ru) 1998-08-27
KR100470739B1 (ko) 2005-09-02
HK1006356A1 (en) 1999-02-26
PL185364B1 (pl) 2003-04-30
KR20040102364A (ko) 2004-12-04
PL321758A1 (en) 1997-12-22
HUP9801746A3 (en) 2000-11-28
EE9700255A (et) 1998-04-15
RO118634B1 (ro) 2003-08-29
NZ303405A (en) 2000-02-28
PT809510E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
FI973118A0 (sv) Lymfotoxin-alfa/beta-komplex och antilymfotoxin-beta-reseptorantikroppar som antitumörmedel
Wang et al. Advancing to the era of cancer immunotherapy
Aragane et al. Involvement of dectin-2 in ultraviolet radiation-induced tolerance
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
YU83600A (sh) Adenozin a3 receptorski modulatori
EP0734264A4 (en) CONNECTIONS SPECIFICALLY BINDING TO COLORECTAL CANCER CELLS AND METHOD FOR THEIR PRODUCTION
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
KIRKPATRICK et al. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma P1798
NO20003552D0 (no) Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte
EP0330201A3 (en) Method of enhancing the effect of cytotoxic agents
GR3007225T3 (sv)
KR950002784A (ko) 종양 반응성 세포가 농후한 림프절의 결정방법, 이의 증식방법, 및 이를 입양 세포 요법에 사용하는 방법
WO1995034320A3 (en) Methods for inhibiting antigen specific t cell responses
UA42806C2 (uk) Система для одночасного трансдермального введення кількох активних начал
Byfield et al. Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
NO20000576L (no) Blanding og fremgangsmåte for regulering av celleproliferasjon og celledød
WO1997041225A3 (en) Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr]
ATE404676T1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
WO1995016709A3 (en) Anti-mullerian hormone receptor polypeptides and antibodies thereto
WO2002053195A3 (en) System for, and method of, irradiating article with x-ray beam
DK0943014T3 (da) Fremgangsmåder til diagnosticering af glaukom og opdagelse af antiglaukome lægemidler
Raleigh et al. Reductive activation of nitroaromatics and enzyme inhibition: Misonidazole and xanthine oxidase
Andres et al. Phylogenetic disparity influences the predominance of direct over indirect pathway of antigen presentation in islet xenotransplantation

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: BIOGEN IDEC MA INC.

Free format text: BIOGEN IDEC MA INC.

FG Patent granted

Ref document number: 119359

Country of ref document: FI